Exclusive License Agreement (Details Narrative) - License Agreement [Member] - USD ($) |
Dec. 31, 2019 |
Jul. 18, 2019 |
Jun. 30, 2019 |
|---|---|---|---|
| Non-refundable payment | $ 400,000 | ||
| Payment due following commencement of first phase III clinical trial of Brilacidin | 1,000,000 | ||
| Payment due upon filing of a marketing approval application | $ 1,000,000 | 1,000,000 | |
| Additional payments payable upon achievement of certain milestones under agreement by related party | $ 24,000,000 |